NextCure, Inc. (NXTC) Stock

NextCure, Inc. is a dynamic clinical-stage biopharmaceutical company focused on pioneering immunomedicines aimed at treating cancer and immune-related disorders by restoring normal immune function. At the forefront of its pipeline is NC318, the company's lead product candidate currently undergoing Phase II clinical trials for advanced or metastatic solid tumors. Additionally, NextCure is advancing NC410, a Phase I immunomedicine designed to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1), and NC762, targeting the B7-H4 protein. The company also explores NC525, a promising LAIR-1 antibody in preclinical trials targeting acute myeloid leukemia and leukemic stem cells. NextCure's innovative approach extends to ongoing research programs evaluating novel immunomodulatory molecules.

Founded in 2015 and headquartered in Beltsville, Maryland, NextCure collaborates closely with academic institutions such as Yale University under licensing agreements to advance its cutting-edge therapies. The company's commitment to scientific excellence and therapeutic innovation underscores its mission to transform cancer treatment paradigms through targeted immune therapies. NextCure continues to expand its portfolio, leveraging deep expertise in immunology to address unmet medical needs and improve patient outcomes globally.

Driven by a passion for advancing cancer immunotherapy, NextCure maintains a robust pipeline of investigational treatments supported by rigorous research and development efforts. With a strong foundation in immunology and a strategic focus on clinical advancements, the company aims to bring novel therapies to patients while striving to redefine standards of care in oncology and immune-related diseases.